Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Crame.

Yesterday, March 4, 2015, 133 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $62.50 to $191,397,755.25.

Highlighted Stocks Traded by Insiders:

American International Group (AIG) - FREE Research Report

Martinez Ronald Eric Jr, who is Executive Vice President at American International Group, sold 10,000 shares at $55.60 on March 4, 2015. Following this transaction, the Executive Vice President owned 30,449 shares meaning that the stake was reduced by 24.72% with the 10,000-share transaction.

The shares most recently traded at $55.55, down $0.05, or 0.09% since the insider transaction. Historical insider transactions for American International Group go as follows:

  • 4-Week # shares bought: 4,720
  • 4-Week # shares sold: 26,810
  • 12-Week # shares bought: 4,720
  • 12-Week # shares sold: 26,810
  • 24-Week # shares bought: 4,720
  • 24-Week # shares sold: 26,810

The average volume for American International Group has been 9.1 million shares per day over the past 30 days. American International Group has a market cap of $76.3 billion and is part of the financial sector and insurance industry. Shares are down 1.12% year-to-date as of the close of trading on Wednesday.

American International Group, Inc. provides insurance products and services for commercial, institutional, and individual customers in the United States, the Asia Pacific, and internationally. The stock currently has a dividend yield of 0.9%. The company has a P/E ratio of 10.6. Currently, there are 9 analysts who rate American International Group a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AIG - FREE

TheStreet Quant Ratings rates American International Group as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full American International Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Omnicare (OCR) - FREE Research Report

Wallman Amy, who is Director at Omnicare, sold 1,874 shares at $77.44 on March 4, 2015. Following this transaction, the Director owned 36,805 shares meaning that the stake was reduced by 4.85% with the 1,874-share transaction.

The shares most recently traded at $75.31, down $2.13, or 2.83% since the insider transaction. Historical insider transactions for Omnicare go as follows:

  • 4-Week # shares bought: 1,500
  • 4-Week # shares sold: 5,672
  • 12-Week # shares bought: 1,500
  • 12-Week # shares sold: 5,672
  • 24-Week # shares bought: 1,500
  • 24-Week # shares sold: 5,672

The average volume for Omnicare has been 800,300 shares per day over the past 30 days. Omnicare has a market cap of $7.3 billion and is part of the health care sector and health services industry. Shares are up 3.89% year-to-date as of the close of trading on Wednesday.

Omnicare, Inc. operates as a healthcare services company that specializes in the management of pharmaceutical care in the United States and Canada. It operates through two segments, Long-Term Care Group and Specialty Care Group. The stock currently has a dividend yield of 1.17%. The company has a P/E ratio of 43.2. Currently, there are 6 analysts who rate Omnicare a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OCR - FREE

TheStreet Quant Ratings rates Omnicare as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, solid stock price performance, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Omnicare Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PDC Energy (PDCE) - FREE Research Report

Wakim Kimberly Luff, who is Director at PDC Energy, sold 1,000 shares at $53.73 on March 4, 2015. Following this transaction, the Director owned 16,898 shares meaning that the stake was reduced by 5.59% with the 1,000-share transaction.

The shares most recently traded at $53.34, down $0.39, or 0.73% since the insider transaction. Historical insider transactions for PDC Energy go as follows:

  • 4-Week # shares sold: 6,000
  • 12-Week # shares sold: 6,000
  • 24-Week # shares sold: 6,000

The average volume for PDC Energy has been 1.3 million shares per day over the past 30 days. PDC Energy has a market cap of $1.9 billion and is part of the basic materials sector and energy industry. Shares are up 31.6% year-to-date as of the close of trading on Wednesday.

PDC Energy, Inc., an independent exploration and production company, acquires, explores for, develops, and produces crude oil, natural gas, and natural gas liquids in the United States. The company has a P/E ratio of 18.4. Currently, there are 13 analysts who rate PDC Energy a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PDCE - FREE

TheStreet Quant Ratings rates PDC Energy as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and weak operating cash flow. Get the full PDC Energy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null